Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen    QGEN   NL0012169213

QIAGEN

(QGEN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

QIAGEN N.V.: Release of a capital market information

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/11/2019 | 12:05pm EDT

DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Buyback
QIAGEN N.V.: Release of a capital market information

11.06.2019 / 18:01
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting

With disclosure dated May 10, 2019, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a fourth tranche of up to USD 50 million under the share repurchase program originally announced on January 31, 2018.

The number of shares which have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) within the framework of such tranche of the share repurchase program in the time period from June 3, 2019 until and including June 7, 2019 amounts to 88,904 shares.

Shares were bought back as follows:

Date Number of Shares Average Price Purchased Volume
acquired (EUR) (EUR)
3 June 2019 22,568 34.0747 768,997.83
4 June 2019 16,812 33.8441 568,987.01
5 June 2019 16,602 34.2713 568,972.12
6 June 2019 16,447 34.6554 569,977.36
7 June 2019 16,475 34.5969 569,983.93
Total 88,904 34.2720 3,046,918.25

The underlying individual trades are published on the website of QIAGEN N.V. (http://corporate.qiagen.com/investor-relations/share-information/ share-buyback).

The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from May 10, 2019 until and including June 7, 2019 amounts to 693,458 shares.

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

Venlo, 11 June 2019

Managing Board

###
Contacts:

QIAGEN
Investor Relations
John Gilardi
+49 2103 29 11711
e-mail: ir@qiagen.com

Public Relations
Dr. Thomas Theuringer
+49 2103 29 11826
e-mail: pr@qiagen.com



11.06.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Internet: www.qiagen.com

 
End of News DGAP News Service

822731  11.06.2019 

fncls.ssp?fn=show_t_gif&application_id=822731&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on QIAGEN
07/16QIAGEN N.V. : to Report Second Quarter and First Half of 2019 Results
BU
07/15QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
07/09QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/25QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/25QIAGEN : Clinical Insight surpasses 1 million patient test cases analyzed and in..
AQ
06/24QIAGEN N.V. : Release of a capital market information
EQ
06/21QIAGEN : New NGS panel for rare and inherited diseases with advanced bioinformat..
AQ
06/21QIAGEN : QCI-Lab performing expanded carrier screening boosts efficiency by 80%
AQ
06/20QIAGEN : Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed and In..
BU
More news
Financials (USD)
Sales 2019 1 578 M
EBIT 2019 430 M
Net income 2019 210 M
Debt 2019 771 M
Yield 2019 -
P/E ratio 2019 44,7x
P/E ratio 2020 35,0x
EV / Sales2019 6,15x
EV / Sales2020 5,54x
Capitalization 8 943 M
Chart QIAGEN
Duration : Period :
Qiagen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 42,23  $
Last Close Price 39,54  $
Spread / Highest target 26,5%
Spread / Average Target 6,81%
Spread / Lowest Target -8,95%
EPS Revisions
Managers
NameTitle
Peer Michael Schatz Chief Executive Officer & Managing Director
Sven Håkan Björklund Chairman-Supervisory Board
Douglas Liu Senior Vice President-Global Operations
Manuel O. Mendez Senior Vice President-Global Commercial Operations
Roland Sackers Chief Financial Officer & Managing Director
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN15.70%0
IQVIA HOLDINGS INC35.39%31 022
LONZA GROUP31.57%25 219
CELLTRION, INC.--.--%19 601
INCYTE CORPORATION26.66%17 436
EXACT SCIENCES CORPORATION85.26%15 096